Abstracts tagged "T cells and salivary gland"

Abstract Number: 2873 • 2017 ACR/ARHP Annual Meeting
DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Hiroyuki Takahashi, Hiroto Tsuboi, Hiromitsu Asashima, Hanae Kudo, Yuko Ono, Saori Abe, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose:Some reports on DNA microarray analysis in labial salivary glands (LSGs) of Sjögren’s syndrome (SS) and healthy controls (HCs) showed that the genes associated with…
Abstract Number: 1055 • 2015 ACR/ARHP Annual Meeting
Expansions of Salivary Gland CD4+ T Cells from Sjögren’s Syndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures of Disease
Michelle L. Joachims¹, Kerry M. Leehan^2,3, Christina M. Lawrence³, Astrid Rasmussen³, Lida Radfar⁴, David M. Lewis⁵, Glen D Houston⁶, Kiely Grundahl³, Donald U. Stone^7,8, Kimberly Hefner⁹, R. Hal Scofield^2,10,11, Kathy L. Sivils^2,3, Linda F. Thompson¹² and A. Darise Farris^1,2, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁵College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Heartland Pathology, Oklahoma City, OK, ⁷Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Hefner Eye Care and Optical Center, Oklahoma City, OK, ¹⁰College of Medicine, Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: CD4+ T cells predominate in salivary gland (SG) focal lymphocytic infiltrates in primary Sjögren’s syndrome (pSS). However, their antigen specificity, degree of clonal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].